Historical Valuation
Connect Biopharma Holdings Ltd (CNTB) is now in the Fair zone, suggesting that its current forward PS ratio of 46251.92 is considered Fairly compared with the five-year average of -3.49. The fair price of Connect Biopharma Holdings Ltd (CNTB) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.23
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Connect Biopharma Holdings Ltd (CNTB) has a current Price-to-Book (P/B) ratio of 2.54. Compared to its 3-year average P/B ratio of 0.77 , the current P/B ratio is approximately 231.28% higher. Relative to its 5-year average P/B ratio of 1.03, the current P/B ratio is about 147.27% higher. Connect Biopharma Holdings Ltd (CNTB) has a Forward Free Cash Flow (FCF) yield of approximately -30.53%. Compared to its 3-year average FCF yield of -83.90%, the current FCF yield is approximately -63.61% lower. Relative to its 5-year average FCF yield of -85.56% , the current FCF yield is about -64.32% lower.
P/B
Median3y
0.77
Median5y
1.03
FCF Yield
Median3y
-83.90
Median5y
-85.56
Competitors Valuation Multiple
AI Analysis for CNTB
The average P/S ratio for CNTB competitors is 7730.84, providing a benchmark for relative valuation. Connect Biopharma Holdings Ltd Corp (CNTB.O) exhibits a P/S ratio of 46251.92, which is 498.28% above the industry average. Given its robust revenue growth of -98.69%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CNTB
1Y
3Y
5Y
Market capitalization of CNTB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CNTB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CNTB currently overvalued or undervalued?
Connect Biopharma Holdings Ltd (CNTB) is now in the Fair zone, suggesting that its current forward PS ratio of 46251.92 is considered Fairly compared with the five-year average of -3.49. The fair price of Connect Biopharma Holdings Ltd (CNTB) is between to according to relative valuation methord.
What is Connect Biopharma Holdings Ltd (CNTB) fair value?
CNTB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Connect Biopharma Holdings Ltd (CNTB) is between to according to relative valuation methord.
How does CNTB's valuation metrics compare to the industry average?
The average P/S ratio for CNTB's competitors is 7730.84, providing a benchmark for relative valuation. Connect Biopharma Holdings Ltd Corp (CNTB) exhibits a P/S ratio of 46251.92, which is 498.28% above the industry average. Given its robust revenue growth of -98.69%, this premium appears unsustainable.
What is the current P/B ratio for Connect Biopharma Holdings Ltd (CNTB) as of Jan 09 2026?
As of Jan 09 2026, Connect Biopharma Holdings Ltd (CNTB) has a P/B ratio of 2.54. This indicates that the market values CNTB at 2.54 times its book value.
What is the current FCF Yield for Connect Biopharma Holdings Ltd (CNTB) as of Jan 09 2026?
As of Jan 09 2026, Connect Biopharma Holdings Ltd (CNTB) has a FCF Yield of -30.53%. This means that for every dollar of Connect Biopharma Holdings Ltd’s market capitalization, the company generates -30.53 cents in free cash flow.
What is the current Forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB) as of Jan 09 2026?
As of Jan 09 2026, Connect Biopharma Holdings Ltd (CNTB) has a Forward P/E ratio of -1.96. This means the market is willing to pay $-1.96 for every dollar of Connect Biopharma Holdings Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Connect Biopharma Holdings Ltd (CNTB) as of Jan 09 2026?
As of Jan 09 2026, Connect Biopharma Holdings Ltd (CNTB) has a Forward P/S ratio of 46251.92. This means the market is valuing CNTB at $46251.92 for every dollar of expected revenue over the next 12 months.